Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Prostatic Neoplasms 2Melanoma 2Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1

Interventions

Cyclophosphamide 48fludarabine phosphate 45fludarabine 38Whole-Body Irradiation 38Mycophenolic Acid 37Imatinib Mesylate 36nilotinib 34Tacrolimus 30Busulfan 23Cyclosporine 18Melphalan 17Granulocyte Colony-Stimulating Factor 17Dasatinib 17thymoglobulin 16Methotrexate 16Thiotepa 15Peripheral Blood Stem Cell Transplantation 15Antilymphocyte Serum 15bosutinib 13Filgrastim 13Stem Cell Transplantation 11sargramostim 8ponatinib 8Cytarabine 8Cyclosporins 8Cord Blood Stem Cell Transplantation 8Clofarabine 8Sirolimus 7Rituximab 7plerixafor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Protein Subunit Vaccines × Clear all
NCT00415857 2018-08-21

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

M.D. Anderson Cancer Center

Phase 2 Terminated
5 enrolled 3 charts
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡